

DAFTAR PUSTAKA

1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. *IDF Diabetes Atlas. Diabetes Research and Clinical Practice* 2014 ; 103 : 137-149
2. Ramachandran A, Snehalatha C, Ma RCW. Diabetes in South-East Asia : An update. *Diabetes Research and Clinical Practice* 2014 ; 103 : 231-237
3. Mehrotra R, Zadeh KK, Adler S. Assessment of glycemic control in dialysis patients with diabetes ; glycosilated hemoglobin or glycated albumin? *Clin J Am Soc Nephrol* 2011 ; 6 : 1520-1522
4. Bandeira SM, Fonseca LJS, Guedes GS, Rabelo LA, Goulart MOF, Vasconcelos SM. Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus. *Int J Mol Sci* 2013 ; 14 : 3265-3284
5. American Diabetes Association. Standards of medical care in diabetes 2010. *Diabetes Care* 2010 ; 33 : s11-s61
6. Lee SY, Choi ME. Urinary biomarkers for early diabetic nephropathy : beyond albuminuria. *Pediatr Nephrol* 2014 ; 10 : s00467
7. Manaf A. Tetrad concept in glycemic control ; the role of glucose variability in chronic complication. Dalam : Manaf A, editor. Naskah lengkap Forum Endokrinologi dan Diabetes Sumatera-6 ; 22-23 Maret 2014 ; Padang : PERKENI Cabang Padang-PERKENI Cabang di Sumatera, 2014 :131-141
8. Wang W, Lee ET, Howard BV, Fabsitz RR, Devereux RB, Welty TK. Fasting plasma glucose and hemoglobin A1c in identifying and predicting diabetes. *Diabetes Care* 2011 ; 34 : 363-368
9. Monnier L, Colette C. Glycemic variability. *Diabetes Care* 2008 ; 31 (Suppl 2) : S150-S154
10. Dinu IR, Mota E. Glycated albumin- more than the missing link in the evaluation of diabetes control. *Rom J Diabetes Nutr Metab Dis* 2014 ; 21 (2) : 137-150
11. Peacock TP, Shihabi ZK, Bleyer AJ, Dolbare EL, Byers JR, Knovich MA et al. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. *Kidney International* 2008 ; 73 : 1062-1068
12. Koga M, Murai J, Morita S, Saito H, Kasayama S. Comparison of annual variability in HbA1c and glycated albumin in patients with type 1 vs type 2 diabetes mellitus. *Journal of Diabetes and Its Complications* 2013 ; 27 (3) : 211-213

13. Okada T, Nakao T, Matsumoto H, Nagaoka Y, Tomaru R, Iwasawa H et al. Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease. *Intern Med* 2011 ; 50 : 23-29
14. Ma XJ, Pan JM, Bao YQ. Combined assessment of glycated albumin and fasting plasma glucose improves the detection of diabetes in Chinese subjects. *Clin Exp Pharmacol Physiol* 2010 ; 37 : 974-979
15. Rodriguez DL, Castelao AM, Gorriz JL, Alvaro FD, Gonzalez JFN. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. *World J Diabetes* 2012 ; 3(1) : 7-18
16. Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC. Oxidative stress, anti-oxidant therapies and chronic kidney disease. *Nephrology* 2012 ; 17 : 311-321
17. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. *Crit Care Med* 2010 ; 38 : 838-842
18. Eslami S, Taherzadeh Z, Schultz MJ, Hanna AA. Glucose variability measures and their effect on mortality : a systematic review. *Intensive Care Med* 2011 ; 37 : 583-593
19. Monnier L, Colette C, Mas E, Michel F, Cristol JP, Boegner C et al. Regulation of oxidative stress by glycaemic control : evidence for an independent inhibitory effect of insulin therapy. *Diabetologia* 2010 ; 53 : 562-571
20. Nalysnyk L, Medina MH, Krishnarajah. Glycaemic variability and complications in patients with diabetes mellitus : evidence from a systematic review of the literature. *Diabetes, Obesity and Metabolism, A Journal of Pharmacology and Therapeutics* 2010 ; 12 : 288-298
21. Reddy SG, Kumar RG, Spurthi MK, Saraswati M, Rani SH. Oxidative stress and DNA damage in diabetic nephropathy. *Journal of Analytical Bio-Science* 2013 ; 36 : 175-180
22. Kurutas EB, Gumusalan Y, Cetinkaya A, Dogan E. Evaluation of method performance for oxidative stress biomarkers in urine and biological variations in urine of patients with type 2 diabetes mellitus and diabetic nephropathy. *Biological Procedures Online* 2015 ; 17 : 1-7
23. Ho E, Galougahi KK, Liu CC, Bhindi R, Figtree GA. Biological markers of oxidative stress : Applications to cardiovascular research and practice. *Redox Biology* 2013 ; 1 : 483-491
24. Kangralkar VA, Patil SD, Bandivadekar RM. Oxidative stress and diabetes : A review. *Int Journal of Pharm Appl* 2010 ; 1 : 38-45

25. Nakhjavani M, Esteghamati A, Nowroozi S, Asgarani F, Rashidi A, Khalilzadeh O. Type 2 diabetes mellitus duration: an independent predictor of serum malondialdehyde levels. *Singapore Med J* 2010; 51(7) : 582
26. Shafi T, Sozio SM, Plantinga LC, Jaar BG, Kim ET, Parekh RS et al. Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients. *Diabetes Care* 2013
27. Reutens AT, Atkins RC. Epidemiology of diabetic nephropathy. *Diabetes and Kidney* 2011 ; 170 : 1-7
28. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocyte in health and renal disease. *Am J Physiol Renal Physiol* 2003 ; 285 : F40-F48
29. Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. *Kidney International* 2012 ; 82 : 1010-1017
30. Satchell SC. The glomerular endothelium emerges as a key player in diabetic nephropathy. *Kidney International* 2012 ; 82 : 949 – 951
31. Hara M, Yamagata K, Tomino Y, Saito A, Hirayama Y, Ogasawara S et al. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes : establishment of a highly sensitive ELISA to detect urinary podocalyxin. *Diabetologia* 2012 ; 55 : 2913-2919
32. Bandiara R, Soelaeman MR. Podocyte and Diabetic Kidney Disease. *JKM* 2011 ; 11(1) : 80-91
33. Mehta S, Cabrera VJ, Upputalla R, Jim B. Urinary biomarkers of diabetic nephropathy. *Current Biomarker Findings* 2013 ; 3 : 67-78
34. Jim B, Ghanta M, Qipo A. Dysregulated nephrin in diabetic nephropathy of type 2 diabetes : A cross sectional study. *Plos One* 2012 ; 7 : e36041
35. Ng DPK, Tai BC, Tan E, Leong H, Nurbaya S. Nephriunuria associates with multiple renal traits in type 2 diabetes. *Nephrol Dial Transplant* 2011 ; 26 : 2508-2514
36. Neelofar K, Ahmad J. Amadori albumin in diabetic nephropathy. *Indian J Endocrinol Metab* 2015 ; 19 : 39-46
37. Kohzuma T, Yamamoto T, Uematsu Y, Shihabi ZK, Freedman BI. Basic performance of an enzymatic method for glycated albumin and reference range determination. *Journal of Diabetes Science and Technology* 2011 ; 5 (6) : 1455-1462
38. Cao H, Chen T, Shi Y. Glycation of human serum albumin in diabetes : Impacts on the structure and function. *Current Medicinal Chemistry* 2015 ; 22 : 4-13

39. Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. *Endocrine Journal* 2010 ; 57 : 751-762
40. Lu JM, Ji LN, Gao Y. Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment : A multicenter, prospective study.
41. Zheng CM, Ma WY, Wu cc, Lu KC. Glycated albumin in diabetic patients with chronic kidney disease. *Clinica Chimica Acta* 2012 ; 413 : 1555-1561
42. Inaba M, Okuno S, Kumeda Y, Yamada S, Imanishi Y, Tabata T et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes : Effect of anemia and erythropoietin injection. *J Am Soc Nephrol* 2007 ; 18 : 896-903
43. Shiraki T, Miura Y, Sawada T, Okada T, Sakuraoka Y, Muto T et al. Glycated albumin suppresses glucose induced insulin secretion by impairing glucose metabolism in rat pancreatic cells. *Nutrition and Metabolism* 2011 ; 8 : 20
44. Cohen MP, Shearman CW. Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats. *Physiol Rep* 2013 ; 1 : 1-10
45. Freedman BI, Shenoy RN, Planer JA, Clay KD, Shihabi ZK, Burkart JM et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. *Perit Dial Int* 2010 ; 30 : 72-79
46. Sato Y, Nagao M, Asai A, Nakajima Y, Takaya M, Takeichi N et al. Association of glycated albumin with the presence of carotid plaque in patients with type 2 diabetes. *J Diabetes Invest* 2013 ; 4 : 634-639
47. Yang J, Zhao J, Xiao H, Zhang D, Li G. Study of hemoglobin and human serum albumin glycation with electrochemical techniques. *Electroanalysis* 2011 ; 23 : 463-468
48. Zheng F, Lu W, Jia C, Li H, Wang Z, Jia W. Relationships between glucose excursion and the activation of oxidative stress in patients with newly diagnosed type 2 diabetes or impaired glucose regulation. *Endocr* 2010 ; 37 : 201-208
49. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA* 2006 ; 295 : 1681-1687
50. Wright E, Bacon S, Glass LC. Oxidative stress in type 2 diabetes ; the role of fasting and postprandial glycemia. *Int J Clin Pract* 2006 ; 60 : 308-314
51. Kashihara N, Haruna Y, Kondeti VK, Kanwar YS. Oxidative stress in diabetic nephropathy. *Curr Med Chem* 2010 ; 17(34): 4256-4269.

52. Grotto D, Maria LS, Valentini J, Paniz C, Schmitt G, Garcia SC et al. Importance of the lipid peroxidation biomarkers and methodological aspects for malondialdehyde quantification. *Quim Nova* 2009 ; 9 : 169-74
53. Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So WY, Wanner C et al. Diabetic kidney disease : A clinical update from kidney disease : Improving global outcomes. *Kidney International* 2015 ; 87 : 20-30
54. Cefalu WT. Standards of Medical Care in Diabetes 2015. *The Journal of Clinical and Applied Research and Education* 2015 ; 38 : 1-99
55. Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A et al. The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro and macrovascular complications : Avenues for a mechanistic based therapeutic approach. *Current Diabetes Reviews* 2011 ; 7 : 313-324
56. Tavafi M. Complexity of diabetic nephropathy pathogenesis and design of investigation. *J Renal Inj Prev* 2013 ; 2(2) ; 59-62
57. Son SM. Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes. *Diabetes Metab J* 2012 ; 36 : 190-198
58. Malki AL. Assessment of urinary osteopontin in association with podocyte for early prediction of nephropathy in diabetic patients. *Disease Markers* 2014 ; 5 pages
59. Jha JC, Dahm J, Cooper ME. New insight into the use of biomarkers of diabetic nephropathy. *Advances in Chronic Kidney Disease* 2014 ; 21 : 318-326
60. Kandasamy Y, Smith R, Lumbers ER, Rudd D. Nephrin- a biomarker of early glomerular injury. *Biomarker Research* 2014 ; 2(21) : 1-8
61. Dellamea BS, Pinto LCF, Leitao CB, Santos KG, Canani LHS. Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis. *BMC Medical Genetics* 2014 ; 15 : 1-13
62. Reddy MA, Park JT, Natarajan R. Epigenetics modifications in the pathogenesis of diabetic nephropathy. *Semin Nephrol* 2013 ; 33(4) ; 341-353
63. Furusyo N, Koga T, Ai M, Otokozaawa S, Kohzuma T, Ikezaki E et al. Utility of glycated albumin for the diagnosis of diabetes mellitus in Japanese population study : results from the kyushu and okinawa population study (KOPS). *Diabetologia* 2011 ; 54 : 3028-3036
64. Hilawe EH, Yatsuya H, Aoyama A. Differences by sex in the prevalence of diabetes mellitus, impaired fasting glycaemia and impaired glucose tolerance in Sub-Saharan Africa : a systematic review and meta analysis. *Organ* 2013 ; 91 : n.9
65. Kondaveeti SB, Shaker IA. Evaluation of glycated albumin and microalbuminuria as early risk markers of nephropathy in type 2 diabetes mellitus. *J Investing Biochem* 2013 ; 2(2) : 127-131

66. Zhuo L, Zou G, Li W, Lu J, Ren W. Prevalence of diabetic nephropathy complicating nondiabetic renal disease among Chinese patients with type 2 diabetes mellitus. *European Journal of Medical Research* 2013 ; 18(4)
67. Suastika K, Dwipayana P, Saraswati MR, Gotera W, Budhiarta AA, Sutanegara IN dkk. Prevalence of obesity, metabolic syndrome, impaired fasting glycemia, and diabetes in selected villages of Bali, Indonesia. *Journal of the ASEAN Federation of Endocrine Societies* 2011 ; 26(2)
68. Lopez J, Bailey R, Rupnow M, Annunziata K. Characterization of type 2 diabetes mellitus burden by age and ethnic groups based on a nationwide survey. *Clinical Therapeutics* 2014 ; 36(4) : 494-506
69. Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Trevisan R et al. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus : findings from the renal insufficiency and cardiovascular events. *J Am Geriatr Soc* 2013 ; 61 : 1253-1261
70. Petrica L, Vlad A, Gluhovschi G, Gadalean F, Dumitrascu V, Gluhovschi C et al. Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients. *Plos One* 2014 ; 9(11) e112538
71. Wang N, Xu Z, Han P, Li T. Glycated albumin and ratio of glycated albumin to hemoglobin are good indicators of diabetic nephropathy in type 2 diabetes mellitus. *Diabetes/ Metabolism Research and Reviews* 2016 ; 32
72. Xu Y, Wang L, He J, Bi Y, Li M, Wang T et al. Prevalence and control of diabetes in chinese adults. *JAMA* 2013 ; 310 (9) : 948-959
73. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults. *JAMA* 2012 ; 307 (5) : 491-497
74. Rani AJ, Mythili SV. Study on total antioxidant status in relation to oxidative stress in type 2 diabetes mellitus. *Journal on Clinical and Diagnostic Research* 2014 ; 8 : 108-110
75. Morsi HK, Ismail MM, Gaber HAH, Elbasmy AA. Macrophage migration inhibitory factor and malondialdehyde as potential predictors of vascular risk complications in type 2 diabetes mellitus: Cross sectional case control study in Saudi Arabia. *Hindawi* 2016 ; 8 pages
76. Kumawat M, Sharma TK, Singh I, Singh N, Ghalaut VS, Vardey SK et al. Antioxidant enzymes and lipid peroxidation in type 2 diabetes mellitus with and without nephropathy. *NAJMS* 2013; 5(3) : 213-219
77. Hsu P, Ai M, Kanda R, Chun N, Chen H, Chen W et al. A comparison of glycated albumin and glycosylated hemoglobin for the screening of diabetes mellitus in Taiwan. *Atherosclerosis* 2015 ; 242(1) : 327-333

78. Koga M, Hirata T, Kasayama S, Ishizaka Y, Yamakado M. Body mass index negatively regulates glycosylated albumin through insulin secretion in patients with type 2 diabetes mellitus. *Clinica Chimica Acta* 2015 ; 438 : 19-23
79. Lioudaki E, Stylianou KG, Petrakis I, Kokologiannakis G, Passam A, Mikhailidis DP et al. Increased urinary excretion of podocyte markers in normoalbuminuric patients with diabetes. *Nephron* 2015; 131 : 34-42
80. Shchukina AA, Bobkova IN, Shestakova MV, Vikulova OK, Zuraeva ZT, Mikhaleva OV. Urinary excretion of markers for podocyte injury in patients with diabetes mellitus. *Europe PMC* 2015 ; 87(10) : 62-66
81. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G et al. Nephlin expression is reduced in human diabetic nephropathy. Evidence for a distinct role for glycosylated albumin and angiotensin II. *Diabetes* 2003 ; 52 : 1023-1030
82. Chen G, Xu Y, Lin Y, Lai X, Yao J, Huang B et al. Association study of genetic variant of 17 diabetes-related genes/ loci and cardiovascular risk and diabetic nephropathy in the Chinese She population. *Journal of Diabetes* 2013 ; 5(2) : 136-145
83. Li Y, Min L, Qiugen Z, Di X, Aiju L, Xun Z et al. Advanced oxidation protein products decrease expression of nephlin and podocin in podocytes via ROS-dependent activation of p38 MAPK. *Sci China Life Sci* 2010 ; 53 : 68-77
84. Gu HF, Ma J, Gu KT, Brismar K. Association of intercellular adhesion molecule 1 (ICAM1) with diabetes and diabetic nephropathy. *Frontiers in Endocrinology* 2013 ; 3 : 43-49
85. Bansal S, Siddarth M, Chawla D, Banerjee BD, Madhu SV, Tripathi AK. Advanced glycation end products enhance reactive oxygen and nitrogen species generation in neutrophils in vitro. *Mol Cell Biochem* 2012 ; 361 : 289-296



